Although a peptide vaccine trial in malignant melanoma to characterize the application site after injection of incomplete Freund’s adjuvant showed the induction of dysfunctional CD8+ T cells with minimal IFNγ production and T cell retention [44], we did not observe any such results, potentially due to the addition of XS15 to the vaccine. This evidence concerns the gene CD8A and melanoma.